Drug Profile
WXFL 10030390
Alternative Names: WX 390; WXFL10030390Latest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Cisen Pharmaceutical; Shanghai Jiatan Pharmatech
- Developer Shanghai Jiatan Pharmatech
- Class Antineoplastics; Pyrimidinones; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenocarcinoma; Solid tumours
- No development reported Lymphoma
Most Recent Events
- 25 Aug 2023 Phase-II clinical trials in Adenocarcinoma (Combination therapy, Late-stage disease) in China (PO) (NCT06124963)
- 03 Jan 2023 Shanghai Jiatan Pharmatech completes a phase Ib/IIa trial for Solid tumours (Late-stage disease) in China (PO, Tablet) (NCT06132932)
- 18 Nov 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (PO) (NCT06117566)